US FDA Assesses Over 500 Biopharma Plants Remotely Via Records Review; Refines Process
Executive Summary
Agency may share outcomes of remote record reviews in lieu of inspections at US and foreign facilities.
You may also be interested in...
Remote Assessments A Welcome Option For US FDA, But They’re Not Every Firm’s First Choice
“We're looking to expand the use of this tool make it a more routine part of our operations going forward,” says Michael Dutcher, deputy director, ORA Office of Human and Animal Food Operations. “In general, the response from industry has been pretty positive” about RRAs.
US FDA Explains How It Is Embracing Remote Assessments Post-Pandemic
Agency provides additional details on plans for various remote methods of assessing Rx and OTC drug manufacturing facilities that became popular when investigators were prevented by COVID-19 travel restrictions from visiting sites in person.
US FDA Explains How It Is Embracing Remote Assessments Post-Pandemic
Agency provides new details on plans for various remote methods of assessing manufacturing establishments that became popular when investigators were prevented by COVID-19 pandemic travel restrictions from visiting sites in person.